Anbio Biotechnology
corporate_fare Company Profile
Anbio Biotechnology (NASDAQ:NNNN) is a publicly traded company in the Life Sciences sector. Wiseek monitors NNNN SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- Shareholders Approve Drastic Capital Restructuring: Reverse Split, Trillions in New Shares, and Enhanced Insider Control
- Shareholders to Vote on Reverse Split, Massive Share Authorization, and Super-Voting Share Entrenchment
- Anbio Biotechnology Reports Strong 2025 Net Income & Gross Margin Amidst Cash Burn and Auditor Change
- Anbio Biotechnology Changes Auditor Due to Capacity Concerns, Appoints GGF CPA LTD
- Anbio Biotechnology Appoints Michael Zhang as Independent Director and Audit Committee Chair
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for NNNN, detected from its recent SEC filings · based on capital-structure filings through 2026-07-09.
Shelf Registration Filed · No Immediate Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
NNNN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.